Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week followup from the response-2 trial

Authors
Category Primary study
JournalHaematologica
Year 2017
This article has no abstract
Epistemonikos ID: fc12421834e034237230ef3964cdefcbd06a1498
First added on: Feb 08, 2025